SITAZIT D 10/50 10S

About SITAZIT D 10/50 10S is an oral antidiabetic medication combining Dapagliflozin and Sitagliptin, used to improve glycemic control in adults with type 2 diabetes mellitus. Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that works by reducing glucose reabsorption in the kidneys, leading to increased urinary glucose excretion and a subsequent reduction in blood glucose levels, independent of insulin. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the body's natural ability to lower high blood glucose levels by increasing the active levels of incretin hormones. This dual mechanism of action provides comprehensive glycemic control, addressing different pathways involved in glucose regulation. The combination also offers benefits such as weight management and potential cardiovascular and renal protection, making it a versatile option for managing type 2 diabetes. Uses Management of type 2 diabetes mellitus Improvement of glycemic control Adjunct to diet and exercise For patients inadequately controlled on monotherapy Directions For Use Take one tablet orally once daily, preferably in the morning, with or without food, as directed by your healthcare provider. Benefits Lowers blood glucose effectively Promotes weight loss Offers cardiovascular benefits Provides renal protective effects Enhances natural insulin secretion Reduces glucagon levels Side Effects Genital yeast infections Urinary tract infections Increased urination Nausea Headache Hypoglycemia (especially with other agents) Dizziness Back pain Flu-like symptoms Ketoacidosis (rare) Pancreatitis (rare) Joint pain (arthralgia) Safety Measures Alcohol - Moderate alcohol consumption is generally acceptable, but excessive intake may increase the risk of hypoglycemia or ketoacidosis. Pregnancy - Not recommended during the second and third trimesters. Consult a doctor for alternative management. Breastfeeding - Not recommended during breastfeeding as components may pass into breast milk. Consult a doctor. Liver - Use with caution in patients with liver impairment. No specific dose adjustment for Sitagliptin, but Dapagliflozin data is limited. Kidney - Contraindicated in severe renal impairment (eGFR < 30 mL/min/1.73m_). Dose adjustment for Sitagliptin may be needed. Lung - No direct impact on lung conditions. However, severe illness can affect glucose control. Disclaimer MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment. Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub. Our goal is to complement, not replace, the essential doctor-patient relationship.